Cargando…

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis

The goal of chronic hepatitis B (CHB) therapy is to improve the patient prognosis through the sustained inhibition of viral replication. However, due to the uncertainty and potentially unlimited duration of the treatment course, nucleus(t)ide analogue (NA) resistance and safety, financial costs and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Ya-Li, Shen, Cheng-Li, Chen, Xin-Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2019
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692272/ https://www.ncbi.nlm.nih.gov/pubmed/31417924 http://dx.doi.org/10.12998/wjcc.v7.i14.1784

Ejemplares similares

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA
por: Liu, Ya-Yun, et al.
Publicado: (2018)

Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA
por: Zhou, Jing, et al.
Publicado: (2022)

Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease
por: Khoo, Tiffany, et al.
Publicado: (2021)

Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
por: Spera, Anna Maria
Publicado: (2022)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Hepatitis B virus reactivation in rheumatoid arthritis
por: Wu, Ya-Li, et al.
Publicado: (2022)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Fibrosis regression following hepatitis C antiviral therapy
por: Elsharkawy, Aisha, et al.
Publicado: (2022)

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
por: Baumert, Thomas F., et al.
Publicado: (2017)

Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment
por: Yin, Guo-Qing, et al.
Publicado: (2022)

Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
por: Kawanaka, Miwa, et al.
Publicado: (2021)

Chronic hepatitis B in pregnant women: Current trends and approaches
por: Belopolskaya, Maria, et al.
Publicado: (2021)

Chronic hepatitis B: New potential therapeutic drugs target
por: Leowattana, Wattana, et al.
Publicado: (2022)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients
por: Lee, Hye Won, et al.
Publicado: (2016)

Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients
por: Guo, Jiang, et al.
Publicado: (2021)

Treatment of hepatitis B virus infection in children and adolescents
por: Stinco, Mariangela, et al.
Publicado: (2021)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

Impact of hepatitis B virus infection on hepatic metabolic signaling pathway
por: Shi, Yi-Xian, et al.
Publicado: (2016)

Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA
por: Sekiba, Kazuma, et al.
Publicado: (2018)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease
por: Ladino, Marco, et al.
Publicado: (2017)

Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals
por: Cerrito, Lucia, et al.
Publicado: (2021)

Kidney transplant from donors with hepatitis B: A challenging treatment option
por: Srisuwarn, Praopilad, et al.
Publicado: (2021)

The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs
por: Li, Yanbai, et al.
Publicado: (2023)

Interaction between hepatitis B virus and SARS-CoV-2 infections
por: Xiang, Tian-Dan, et al.
Publicado: (2021)

Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched
por: Compagnoni, Stella, et al.
Publicado: (2021)

Hepatitis B in renal transplant patients
por: Marinaki, Smaragdi, et al.
Publicado: (2017)

Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes
por: Yang, Xiao-Qian, et al.
Publicado: (2019)

Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome
por: Amponsah-Dacosta, Edina, et al.
Publicado: (2020)

Liver injury in COVID-19: Detection, pathogenesis, and treatment
por: Cai, Yue, et al.
Publicado: (2021)

Hepatitis B in patients with hematological diseases: An update
por: Coluccio, Chiara, et al.
Publicado: (2017)

Current evidence on the management of hepatitis B in pregnancy
por: Maraolo, Alberto Enrico, et al.
Publicado: (2018)

Elimination of Hepatitis B: Is It a Mission Possible?
por: Tseng, Tai-Chung, et al.
Publicado: (2017)

Management of hepatitis B and C in special population
por: Kulkarni, Anand V, et al.
Publicado: (2021)

Practical insights into chronic management of hepatic Wilson’s disease
por: Lynch, Erica Nicola, et al.
Publicado: (2022)

Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C
por: Rehman, Syed Tabish, et al.
Publicado: (2021)

Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment
por: Spera, Anna Maria
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r08k3gllufho9siud0qdhi2iok